We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £270,543
Hussle is one of the UK's top fitness marketplace, providing many flexible fitness opportunities according to your requirement. The company has provided c.2.5M gym visits, raised £12M+ to date, and serviced more than 500k customers. The platform has c.40% of UK gyms and c.3,000 fitness venues. Besides a huge customer base, 10,000 new members are added to the facility each month. It has received a rating of 4.7 stars out of 5 on TrustPilot across 1,500 reviews. So far, Hussle has raised £12M+ from Albion, MMC, Concentric, TechnoGym, and Channel 4. With the proceeds, the company aims at creating a globally trusted fitness brand by enhancing the brand's awareness and by broadening the range of physical activities available on the platform.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,440,500
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £200,000
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,048,396
gowithYamo aims to make art more accessible to everyone, from art newbies to experienced gallery-goers through its application. Users can collect Yamo points by checking-in to galleries and exchanging them for rewards such as art prints and exhibition tickets from the company's in-app store. gowithYamo provides support to galleries, museums and artists by exposing them to an active community of art lovers. The company also offers custom-built virtual exhibition spaces where artists can show and sell their work to a sizeable digital audience. gowithYamo has collaborated with art entities like Roy's Art Fair, The Other Art Fair, Harlesden High Street, and many others. It has a social media presence of 50,000+ followers. The company will use 30% of the investment to expand across different demographics, 25% to further finetune its virtual exhibition platform, 20% for marketing, and 25% to implement Artificial Intelligence (AI) in the gowithYamo app to help recommend exhibitions to its users.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £161,105
Bua Fit is easy to use, a simple way to book web application for outdoor fitness classes. It eliminates all the trouble by connecting the trainers to clients for group fitness classes and gives the customers a diversity of trainers. The company has been a finalist in The Great British Entrepreneurial Challenge, has a network of 100 trainers and 42% active user rate since launch. With the proceeds, the company will earn more users, more trainers, more revenue, invest in product development and expand the team.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £205,378
PCL Health is a Business-to-Business (B2B) Software-as-a-Service (SaaS) entity that aims to bring hospital-level care to anyone remotely. It asserts that the correct use of remote monitoring can reduce mortality by up to 45%. PCL Health intends to become a contender in the remote healthcare market that is set to touch $30 billion by 2023. It has developed CE rated medical-grade devices that use health algorithms combined with sensors and its proprietary range of apps to allow family members to proactively monitor the health of their loved ones, alongside carers and doctors, remotely. PCL Health has completed two pilots with 65 people and received a Letter Of Intent (LOI) from a National Health Service (NHS) Trust for a clinical trial. It won the 'Innovative Startup' competition at the 2019 Healthcare Unblocked event. PCL Health will use the investment for technology enhancement, running further pilot studies, and working capital.

Pitch Rated

51%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £394,680
Q Doctor aims at changing the NHS care delivery with the help of video consulting to benefit patients and clinicians. The company is focusing on delivering a model that keeps modernised NHS care free of charge for the patients. The video solution plugs NHS clinicians to the existing NHS infrastructure and allows them to connect to the NHS patients digitally. With the proceeds, Q Doctor will fulfil its strategy for 2020. It will deploy the funds into labour, development, operations, marketing, and contingency funds.

Pitch Rated

51%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,386,200
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.

Pitch Rated

50%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £215,946
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph